Clinical efficacy of combination therapy with recombinant endostatin and cetuximab on advanced non-small cell lung cancer and its impacts on serum TLR4 and vascular endothelial growth factor
Shu Shengguang
Liu Hui
Hu Jiaqing
Zhang Bao
Gao Pengfei
Abstract：Objective To explore the clinical efficacy of combination therapy with recombinant endostatin and cetuximab in advanced non-small cell lung cancer(NSCLC)and its impacts on serum Toll-like receptor 4(TLR4)and vascular endothelial growth factor(VEGF)levels.Methods A total of 120 patients with advanced NSCLC admitted to the Department of Thoracic Surgery,Hunan Second People's Hospital/Hunan Brain Hospital from October 2021 to October 2024 were en-rolled.They were randomly assigned via random number table into a control group(cetuximab,n=60)and an experimental group(recombinant endostatin+cetuximab,n=60).Clinical efficacy,tumor marker levels,TLR4,VEGF,quality of life,and adverse reactions were compared between the two groups.Results The disease control rate in the experimental group was 91.67％,significantly higher than that in the control group(78.33％)(x2/P=4.183/0.041).After three treatment cycles,levels of tissue polypeptide antigen(TPA),carcinoembryonic antigen(CEA),squamous cell carcinoma antigen(SCC),cytokeratin 19 fragment(CYFRA21-1),TLR4,and VEGF in the experimental group were significantly lower than those in the control group,while scores on the Functional Assessment of Cancer Therapy-Lung(FACT-L)scale were significantly higher(t/P=12.137/＜0.001,5.024/＜0.001,5.165/＜0.001,4.798/＜0.001,3.786/＜0.001,4.118/＜0.001,3.740/＜0.001).The total incidence of adverse reactions was 11.67％in the control group and 15.00％in the experimental group,with no statistically significant difference(x2/P=0.288/0.591).Conclusion The combination of recombinant endostatin and cetuximab demonstrates significant clinical efficacy in advanced NSCLC.It effectively reduces tumor marker levels,modulates TLR4 and VEGF expression,improves pa-tient quality of life,and exhibits a favorable safety profile.
Keywords：Advanced non-small cell lung cancerRecombinant endostatinCetuximabToll-Like Receptor 4Vascu-lar endothelial growth factorTherapeutic effect
Publication Date：2025-10-18
Online Publishing Date：2025-11-10(First online date of this platform, not the publication date of the document)
Pages：5( 1183-1187 )